KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.
Also called NCT03236246
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 206 participants
- Sponsor
- Registry
-
NCT03236246
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03236246. Randomized; no masking; primary purpose treatment. Start 2017-08-15 (actual); primary completion 2019-08-30 (actual). Results posted on 2021-03-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)
- Acronym
- COMPASS
- Condition
- Chronic Kidney Diseases
- Condition
- Iron Deficiency Anemia
- Intervention (Drug)
- KRX-0502
- Lead sponsor
- Keryx Biopharmaceuticals
Record details
- Record id
cardio:ct-nct03236246- Content hash
2e1e045e6b033486124e55ecc8fcafd79b2c9e8aa37e4b3cfc1c0bf690d8b789